Trials / Completed
CompletedNCT01367613
Open-Label Treatment Extension of Protocol MNTX 302
A Three-Month Open-Label Treatment Extension of Protocol MNTX 302
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 89 (actual)
- Sponsor
- Bausch Health Americas, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a 3 month open-label extension study that allows patients who completed Protocol MNTX 302 to receive SC MNTX.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SC Methylnaltrexone |
Timeline
- Start date
- 2004-03-01
- Primary completion
- 2006-01-01
- Completion
- 2006-01-01
- First posted
- 2011-06-07
- Last updated
- 2019-11-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01367613. Inclusion in this directory is not an endorsement.